Donanemab (LY3002813) is a humanized IgG1κ monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
| CAS Number | 1931944-80-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] Mark A Mintun, et al. N Engl J Med. Donanemab in Early Alzheimer's Disease
| Related Amyloid Products |
|---|
| Methyl tridecanoate
Methyl tridecanoate inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE). |
| Trontinemab
Trontinemab is a bispecific human IgG1-κ antibody that targets amyloid β A4 precursor protein (APP) and transferrin receptor (TFRC).Trontinemab may be used in Alzheimer's disease-related studies. |
| RAGE antagonist peptide
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. |
| Fmoc-Ala-Glu-Asn-Lys-NH2
Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. |
| β-Amyloid peptide(16-20)
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
